A Pilot Study of Stereotactic Body Radiotherapy (SBRT) and 177Lu-PSMA-617 for the Treatment of Hormone Sensitive, Oligometastatic Prostate Cancer
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 17 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2022 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 12 Jul 2022 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.